CRISPR-Cas systems: ushering in the new genome editing era

Fernando Perez Rojo, Rikard Karl Martin Nyman, Alexander Arthur Theodore Johnson, Maria Pazos Navarro, Megan Ryan, William Erskine, Parwinder Kaur

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.

Original languageEnglish
Pages (from-to)214-221
JournalBioengineered
Volume9
Issue number1
DOIs
Publication statusPublished - 3 Jul 2018

Fingerprint

CRISPR-Associated Proteins
Genes
Proteins
Genetic engineering
Dissent and Disputes
Genetic Engineering
Patents
Gene Editing

Cite this

Perez Rojo, Fernando ; Nyman, Rikard Karl Martin ; Johnson, Alexander Arthur Theodore ; Pazos Navarro, Maria ; Ryan, Megan ; Erskine, William ; Kaur, Parwinder. / CRISPR-Cas systems : ushering in the new genome editing era. In: Bioengineered. 2018 ; Vol. 9, No. 1. pp. 214-221.
@article{8da61dbd7c6e40d6803e11b5acba6c28,
title = "CRISPR-Cas systems: ushering in the new genome editing era",
abstract = "In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.",
author = "{Perez Rojo}, Fernando and Nyman, {Rikard Karl Martin} and Johnson, {Alexander Arthur Theodore} and {Pazos Navarro}, Maria and Megan Ryan and William Erskine and Parwinder Kaur",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/21655979.2018.1470720",
language = "English",
volume = "9",
pages = "214--221",
journal = "Bioengineered",
issn = "2165-5979",
publisher = "Taylor & Francis",
number = "1",

}

CRISPR-Cas systems : ushering in the new genome editing era. / Perez Rojo, Fernando; Nyman, Rikard Karl Martin; Johnson, Alexander Arthur Theodore ; Pazos Navarro, Maria; Ryan, Megan; Erskine, William; Kaur, Parwinder.

In: Bioengineered, Vol. 9, No. 1, 03.07.2018, p. 214-221.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CRISPR-Cas systems

T2 - ushering in the new genome editing era

AU - Perez Rojo, Fernando

AU - Nyman, Rikard Karl Martin

AU - Johnson, Alexander Arthur Theodore

AU - Pazos Navarro, Maria

AU - Ryan, Megan

AU - Erskine, William

AU - Kaur, Parwinder

PY - 2018/7/3

Y1 - 2018/7/3

N2 - In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.

AB - In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.

U2 - 10.1080/21655979.2018.1470720

DO - 10.1080/21655979.2018.1470720

M3 - Article

VL - 9

SP - 214

EP - 221

JO - Bioengineered

JF - Bioengineered

SN - 2165-5979

IS - 1

ER -